Healthcare (SH:603313)2022-10-28 16:00Financial Performance - The company's revenue for Q3 2022 was ¥1,984,887,590.86, representing a decrease of 10.21% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥15,088,201.12, an increase of 107.99% year-over-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥30,431,460.65, up 214.26% from the previous year[6]. - The basic earnings per share for Q3 2022 was ¥0.03, reflecting a growth of 107.14% compared to the same period last year[9]. - The diluted earnings per share for Q3 2022 was ¥0.06, an increase of 114.29% year-over-year[9]. - The company achieved a year-to-date net profit growth of 154.83% compared to the same period last year[12]. - Net profit for the third quarter of 2022 was CNY 110,466,841.91, a significant recovery from a net loss of CNY 162,568,503.97 in the same quarter of 2021[31]. - The net profit attributable to the parent company shareholders was approximately ¥98.75 million, compared to a net loss of ¥180.11 million in the previous period[34]. - The total comprehensive income amounted to ¥125.17 million, a significant improvement from a total comprehensive loss of ¥251.04 million in the prior period[34]. - Basic earnings per share were ¥0.20, recovering from a loss of ¥0.45 per share in the same period last year[34]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥9,411,691,679.99, a 2.32% increase from the end of the previous year[9]. - The equity attributable to shareholders at the end of Q3 2022 was ¥3,009,100,998.08, up 3.52% from the previous year[9]. - Total current assets as of September 30, 2022, amounted to ¥4,183,439,658.82, a decrease from ¥4,422,727,810.71 at the end of 2021, representing a decline of approximately 5.4%[22]. - The company's total assets increased to CNY 9,411,691,679.99 from CNY 9,198,519,914.62, representing a growth of 2.3%[28]. - Non-current liabilities totaled CNY 2,117,474,388.64, up from CNY 2,014,843,000.18, indicating an increase of approximately 5.1%[28]. - The total liabilities increased to CNY 6,326,277,542.43 from CNY 6,204,638,697.98, marking a rise of about 2%[28]. - The equity attributable to shareholders rose to CNY 3,009,100,998.08 from CNY 2,906,893,844.75, an increase of approximately 3.5%[28]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥240,422,909.25, a significant increase of 171.15%[6]. - Cash flow from operating activities generated a net inflow of approximately ¥240.42 million, contrasting with a net outflow of ¥337.91 million in the previous year[36]. - Cash inflow from investment activities totaled approximately ¥70.23 million, compared to ¥18.59 million in the same period last year[36]. - Cash outflow for investment activities was approximately ¥485.70 million, an increase from ¥435.79 million in the previous year[38]. - Cash flow from financing activities resulted in a net outflow of approximately ¥180.67 million, compared to a net inflow of ¥324.38 million in the same period last year[38]. - The ending cash and cash equivalents balance was approximately ¥513.41 million, down from ¥530.42 million in the previous year[38]. - The company received approximately ¥2.29 billion in cash from borrowings, an increase from ¥2.01 billion in the same period last year[38]. - The company reported a significant increase in cash received from operating activities related to other business, totaling approximately ¥180.72 million, compared to ¥66.16 million in the previous year[36]. Shareholder Information - The company has a total of 28,013 common shareholders at the end of the reporting period[16]. - The top ten shareholders hold a combined total of 287,000,000 shares, representing approximately 58.5% of the total shares[16]. Operational Costs and Expenses - Total operating costs decreased to CNY 5,900,213,818.44 from CNY 6,087,652,851.56, reflecting a reduction of approximately 3.1%[28]. - Research and development expenses for the third quarter were CNY 74,781,215.10, down from CNY 93,957,318.57, showing a decrease of about 20.4%[31]. - The company reported a decrease in sales expenses to CNY 1,004,236,023.72 from CNY 917,094,139.67, reflecting an increase of approximately 9.5%[31]. Litigation - The company is involved in ongoing litigation with BJ and UM Company, with a potential liability of approximately ¥122,642,664.90 as of the balance sheet date[19]. Financial Asset Changes - The company reported a non-recurring loss from the fair value changes of financial assets amounting to -¥18,475,108.63 for Q3 2022[11]. - The company reported a significant decrease in trading financial assets from ¥61,073,889.24 to ¥20,504,836.88, a decline of about 66.5%[22]. - Long-term equity investments rose to ¥119,556,769.22 from ¥70,944,191.47, indicating an increase of approximately 68.5%[22]. - Other receivables decreased to ¥87,475,537.12 from ¥106,902,620.42, reflecting a decrease of approximately 18.2%[22]. - Accounts receivable increased to ¥1,405,926,928.38 from ¥1,125,245,842.66, marking an increase of approximately 24.8%[22]. - Inventory decreased slightly to ¥1,912,966,771.72 from ¥1,939,131,042.06, a reduction of about 1.4%[22].